September 3, 2013 – FDA requires manufacturers of olmesartan-containing blood pressure medications to update their labeling with a warning about sprue-like enteropathy.
September 3, 2013 – FDA requires manufacturers of olmesartan-containing blood pressure medications to update their labeling with a warning about sprue-like enteropathy.